source
- UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNews of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.BioPharma Dive · 3mo ago↗ source
- Avalyn's upsized IPO; Alector ends another study in GSK partnership🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday ...Endpoints · 3mo ago↗ source
- Analysts focus on three programs in big year for Bristol MyersWall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected by…